sub:assertion {
  drugbank:DB00321 a biolink:Drug ;
    rdfs:label "Amitriptyline" ;
    biolink:category biolink:Drug .
  mondo:0100081 a biolink:Disease ;
    rdfs:label "sleep disorder" ;
    biolink:category biolink:Disease .
  sub:association rdf:object mondo:0100081 ;
    rdf:predicate biolink:treats ;
    rdf:subject drugbank:DB00321 ;
    a biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    rdfs:label "Among TCAs, doxepin (sinequan) appears to be best suited for managing insomnia in healthy adults. Doxepin works as a selective antagonist to H(1) receptors, which promote the initiation and maintenance of sleep (Owen, 2009) (Table 2). Ultra-low doses of this drug (< 6 mg per day) significantly improve and sustain both maintenance and duration of sleep (Rojas-Fernandez and Chen, 2014; Weber et al., 2010). Another frequently prescribed TCA is amitriptyline, which as a long-term option is found to be effective for patients with ongoing sleep problems (Everitt et al., 2014; Pagel and Parnes, 2001)." ;
    biolink:aggregator_knowledge_source infores:knowledge-collaboratory ;
    biolink:category biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    biolink:has_population_context sub:context ;
    biolink:publications pmid:31622593 ;
    biolink:relation ncit:C94303 .
  sub:context a biolink:Cohort ;
    rdfs:label "Adults" ;
    biolink:category biolink:Cohort .
}